News stories about Advaxis (NASDAQ:ADXS) have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Advaxis earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 47.5129085727683 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
- Traders Watch list: Digital Turbine, Inc. (NASDAQ:APPS), Advaxis … – The Oracle Examiner (oracleexaminer.com)
- Most Recent Figure Make This Stock Even More Attractive – Advaxis … – Alpha Beta Stock (alphabetastock.com)
- Profitability Ratios in Focus: Advaxis, Inc. (ADXS) – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Investors are Unsure How to React (Brief Analysis) – Advaxis Inc (NASDAQ: ADXS) – Stock Trading Point (press release) (stocktradingpoint.com)
- Stock Watch Evaluation – Advaxis Inc (NASDAQ: ADXS) – Alpha Beta Stock (alphabetastock.com)
Several equities research analysts have issued reports on ADXS shares. Cantor Fitzgerald cut their price objective on shares of Advaxis from $19.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, March 13th. ValuEngine upgraded shares of Advaxis from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, HC Wainwright set a $6.00 price target on shares of Advaxis and gave the company a “buy” rating in a research report on Wednesday, March 14th.
Advaxis (NASDAQ:ADXS) last released its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.06. Advaxis had a negative net margin of 940.64% and a negative return on equity of 149.14%. The company had revenue of $2.06 million during the quarter, compared to the consensus estimate of $3.03 million. research analysts predict that Advaxis will post -1.73 EPS for the current year.
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.